This section contains information intended for healthcare professionals. Please certify that you are a healthcare professional.

Please indicate your country of residence:

What language is your preference?

Show filters
Resources type
Filter by Resources type
Pathologies
Filter by Pathologies
Technologies
Filter by Technologies
Instruments
Filter by Instruments
71 result(s) found
Sort by:

May. 17, 2024 May. 20, 2024

Event
Ljubljana, Slovenia

14th International Congress on Autoimmunity 2024, Ljubljana, Slovenia

Sebia booth #15

Learn more

Sebia receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices

Press Release
Apr. 11, 2024

The next generation instrument for screening hemoglobin disorders in newborns.

Apr. 18, 2024 Apr. 20, 2024

Event
Torino, Italy

European Myeloma Network Meeting – EMN 2024

Sebia booth: #9

Learn more

Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays

Press Release
Mar. 06, 2024

Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.

Sebia UK Carbon reduction plan – 2022

News
Mar. 01, 2024

Sebia’s commitment to carbon neutrality.

How External Quality Assessment supports quality improvement in laboratory hemoglobinopathy diagnosis

Webinar
Feb. 19, 2024

Educational Workshop with Dr. Barbara De la Salle

HYDRASYS 2 SCAN FOCUSING: Overview

Video
Feb. 13, 2024

Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.

Sebia launches M-inSight®, a test for monitoring multiple myeloma patients

Press Release
Dec. 04, 2023

Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma